WO2024121805 - SOLID STATE FORMS OF ZIPALERTINIB AND PROCESS FOR PREPARATION THEREOF
National phase entry:
Publication Number
WO/2024/121805
Publication Date
13.06.2024
International Application No.
PCT/IB2023/062398
International Filing Date
08.12.2023
Title **
[English]
SOLID STATE FORMS OF ZIPALERTINIB AND PROCESS FOR PREPARATION THEREOF
[French]
FORMES À L'ÉTAT SOLIDE DE ZIPALERTINIB ET LEUR PROCÉDÉ DE PRÉPARATION
Applicants **
ASSIA CHEMICAL INDUSTRIES LTD.
Inventors
KOLESA, Pavel
ROMANOVÁ, Jana
JEGOROV, Alexandr
Priority Data
63/431,103
08.12.2022
US
63/449,079
01.03.2023
US
63/458,186
10.04.2023
US
63/466,392
15.05.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2695 | |
| EPO | Filing, Examination, Granting | 12506 | |
| Japan | Filing, Examination, Granting | 2368 | |
| South Korea | Filing, Examination, Granting | 2509 | |
| USA | Filing, Examination, Granting | 4940 |
Total:
25,018
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure encompasses solid state forms of Zipalertinib, and of Zipalertinib complexes, in embodiments crystalline polymorphs of Zipalertinib and of Zipalertinib complexes, processes for preparation thereof, and pharmaceutical compositions thereof.[French]
La présente divulgation concerne des formes à l'état solide de Zipalertinib, et de complexes de Zipalertinib, dans des modes de réalisation des polymorphes cristallins de Zipalertinib et de complexes de Zipalertinib, des procédés de préparation de ceux-ci, et des compositions pharmaceutiques de ceux-ci.